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AbstractNext-generation sequencing (NGS) efforts have established catalogs of mutations
relevant to cancer development. However, the clinical utility of this information remains
largely unexplored. Here, we present the results of the first eight patients recruited into a
clinical whole-genome sequencing (WGS) program in the United Kingdom. We performed
PCR-freeWGS of fresh frozen tumors and germlineDNA at 75× and 30×, respectively, using
the HiSeq2500 HTv4. Subtracted tumor VCFs and paired germlines were subjected to com-
prehensive analysis of coding and noncoding regions, integration of germline with somati-
cally acquired variants, and global mutation signatures and pathway analyses. Results were
classified into tiers and presented to amultidisciplinary tumor board.WGS results helped to
clarify an uncertain histopathological diagnosis in one case, led to informed or supported
prognosis in two cases, leading to de-escalation of therapy in one, and indicated potential
treatments in all eight. Overall 26 different tier 1 potentially clinically actionable findings
were identified using WGS compared with six SNVs/indels using routine targeted NGS.
These initial results demonstrate the potential ofWGS to inform future diagnosis, prognosis,
and treatment choice in cancer and justify the systematic evaluation of the clinical utility of
WGS in larger cohorts of patients with cancer.
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INTRODUCTION
Recent international research programs have provided a comprehensive catalog of the ge-
nomic landscape of cancer and provided insights into the temporal and spatial heterogene-
ity of tumors. These studies used high-throughput next-generation sequencing technology
(HTS) to reveal single-nucleotide variants (SNVs) and small indels (Pleasance et al. 2010a,b;
Banerji et al. 2012; The Cancer Genome Atlas Network 2012; Curtis et al. 2012; Ellis et al.
2012; Shah et al. 2012; Stephens et al. 2012) in protein-coding regions that comprise
<1% of the human genome. The clinical utility and cost-effectiveness of targeted next-gen-
eration sequencing (TGS) cancer panel testing to detect somatically acquired single gene
mutations is now established in specific disease areas, such as lung and melanoma
(Hamblin et al. 2017), and are illustrated by the efficacy of a number of therapeutics targeting
the protein products of specific genes that are altered in human cancer. Molecular alterations
have also been shown to have predictive and/or prognostic implications (Amado et al. 2008;
Parsons et al. 2008).
However, the breadth and significance of various mutation types across multiple genes
affecting biological pathways relevant to cancer and their potential clinical significance are
largely unexplored. Whole-genome sequencing (WGS) can provide a comprehensive as-
sessment of the mutational spectra of cancers across the entire genome. Those that may
be of particular clinical relevance can be divided into five broad, evidence-based areas of
analysis.
The first comprises mutations in untranslated, intronic, and intergenic regions. Common
inherited variants conferring susceptibility to human disease are found frequently in noncod-
ing regulatory or intronic regions. The possibility that similar mechanisms operate somati-
cally in cancer was highlighted by the discovery of potentially targetable somatic driver
substitutions in the TERT gene promoter (Huang et al. 2013; Vinagre et al. 2013; Khurana
et al. 2016; Smith et al. 2016) and more recently in NOTCH1 splice region and a PAX5 en-
hancer (Puente et al. 2015).
The second area (Lin et al. 2013) addresses complex types of mutations such as copy-
number aberrations (CNAs) and translocations that have not been integrated systematically
with SNV analyses and linked to clinical outcome or response to therapy such as CN losses
and/or SNVs involving the TP53 locus at 17p13.1 in chronic lymphocytic leukemia (Zenz et al.
2010; Dreger et al. 2013; te Raa et al. 2013) and translocations (Manolov andManolova 1972;
Rowley 1973; Dalla-Favera et al. 1982; Larson et al. 1984; Shtivelman et al. 1985; Dreazen
et al. 1987; Parker and Zhang 2013).
The third set of analyses includes the comprehensive investigation ofmolecular pathways
such as DNA damage response (DDR) pathways. All cells rely onmultiple DDR pathways spe-
cialized in the repair of specific forms of DNA damage. Genes involved in these DDR path-
ways are among the most frequently mutated genes in cancer. Whereas a defect in a single
DDR pathway is compatible with cell viability, a combination of defects in two DDR pathways
leads to cell death, a concept known as synthetic lethality. Synthetic lethality can be induced
by small-molecule drugs, and exploitation of a tumor’s defective DDR pathway has been
shown to be an effective therapeutic strategy. For example, synthetic lethality of BRCA1/2
mutations causing defective homologous recombination repair (HRR) is induced by cisplatin
or PARP inhibition and has been confirmed in clinical trials (Fong et al. 2009; Fong et al.
2010; Ledermann et al. 2012).
Comprehensive analysis of combinations of constitutional and/or somatically acquired
base substitution, indels, rearrangements, and CN changes across all genes involved in
HRR-based DNA double-strand break repair may yield better predictors of responsiveness
to drugs targeting this pathway than BRCA1/2 mutations or promoter methylation alone
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(Waddell et al. 2015). Constitutional or somatically acquired biallelic mutations in a number
of genes associated with DDR have been defined recently and evaluated prospectively in
clinical trials (Mateo et al. 2015; Pritchard et al. 2016). In particular, somatic and germlinemu-
tations in ATM, ATR, PTEN, PALB2, RAD51C, RAD50, TP53, CHEK2, BRIP1, FANCA,
HDAC2, MLH3, ERCC3, MRE11, andNBN have been associated with synthetic lethality after
treatment with PARP inhibitors and other emerging potential therapeutics (Riabinska et al.
2013; Dietlein et al. 2014; Mateo et al. 2015; Kristeleit et al. 2016). Furthermore, in addition
to HRR and MMR, other DDR key pathways are now being targeted in the clinic (Pritchard
et al. 2016; Stover et al. 2016). The fourth area involves investigating global measures
such as the absolute mutational burden and mutation signatures. These measures are not
routinely investigated in the clinical setting yet but can point to particular subtypes of cancer
with defective mismatch repair that are associated with favorable prognosis (Tan et al. 2008;
Alexandrov et al. 2013a,b; Maccaroni et al. 2015; Nik-Zainal et al. 2016) and may benefit
from immune checkpoint inhibition (Heemskerk et al. 2013; Chabanon et al. 2016). Recent
studies have demonstrated a direct relationship between exonic mutational burden, durable
sensitivity to PD-1 and CTLA-4 blockade, and overall survival (Santin et al. 2015;
McGranahan et al. 2016; Strickland et al. 2016).
The fifth and final approach includes the systematic analysis of targetable germline var-
iants and integration with somatic variant calling in all patients with cancer rather than limit-
ing analysis to patients with a Mendelian pattern of inheritance and early onset. This avenue
is important as (1) most targeted clinical cancer sequencing does not include analysis of the
germline and (2) the “first hit” of cancer pathogenesis might be present in the germline and
will be subtracted during routine whole-exome sequencing (WES) or WGS tumor bioinfor-
matics analysis, so that biallelic mutations, such as those in DDR pathways described above,
will be missed.
Although WES can identify many of the mutation types described above, not all known
cancer driver genes are captured by this technique and identification of complex rearrange-
ments and copy-number abnormalities, particularly those involving noncoding regions, may
not be detected. WGS allows the robust detection of all mutation types including complex
somatically acquired changes. Although the feasibility of WGS in the clinical management of
cancer patients has been described previously (Laskin et al. 2015), there are currently no
published studies evaluating the utility of WGS in the clinical management of cancer pa-
tients beyond the detection of clinically actionable single gene variants. The aim of our
study was to utilize WGS to comprehensively profile affectedmolecular pathways and global
mutation signatures that would pinpoint clinically actionable events in patients with ad-
vanced cancers.
RESULTS
Overview
This study describes the clinically actionable mutations arising from WGS of the first eight
consecutive patients recruited to a clinical genome sequencing program in the UK. The clin-
ical characteristics of each case are described in Table 1 and the corresponding histology
images are shown in Figure 1.
A summary of the total number of somatic SNVs, CNAs, and SVs and a breakdown of
these variants by the tier 1,2,3 classification system for each of the cases (1–8) is shown in
Supplemental Table S1. These results show that the total number of somatic mutations
per case is very variable, with two cases (Cases 5 and 7) demonstrating a hypermutated ge-
notype as described below.
Clinical WGS in cancer
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Figure 1. Histology of each tumor sequenced. Histology images of tumors resected or biopsied from Cases
1–8; sections were obtained from formalin-fixed, paraffin-embedded tissue stained with hematoxylin and eo-
sin (H&E). A–E and H were scanned at ×200, F and G were photographed at ×100 and ×40, respectively. (A)
Case 1: Skin biopsy showing infiltration of the dermis (center) by a poorly defined tumor. (Inset) High magni-
fication showing poorly differentiated carcinoma cells. (B) Case 2: Oral biopsy showing normal area of oral mu-
cosa (upper right) with infiltration of the subepithelial tissue by tumor. (Inset) High magnification
demonstrating a squamous cell carcinoma morphology with a lack of keratinization. (C ) Case 3: Chest wall
core biopsy showing skeletal musclewith widespread tumor invasion. (Inset) Highmagnification showing poor-
ly differentiated carcinoma cells dissecting muscle bundles and infiltrating surrounding tissue. (D) Case 4:
Cecal biopsy showing normal columnar epithelium (upper left) and an area of tumor (right). (Inset) High mag-
nification showing poorly differentiated adenocarcinoma. (E) Case 5: Endometrial resection tissue demonstrat-
ing a large poloidal mass filling the uterine cavity with showing glandular and papillary areas. Background
endometrium below. (Inset) High magnification showing the mixed appearance of the tumor. (F ) Case 6:
Rib biopsy at lowmagnification showing partially necrotic bone and cartilage (upper left) and cartilage infiltrat-
ed by a high grade tumor (central). (Inset) High magnification demonstrating neuroendocrine (small cell) dif-
ferentiation. (G) Case 7: Left thigh core biopsy at low magnification showing inflamed and necrotic tissue
with islands of poorly differentiated tumor. (Inset, left) Highmagnification demonstrating the dominant epithe-
lioid appearance of the tumor. (Inset, right) High magnification of a spindle cell component also present. (H)
Case 8: Cervical vertebral tumor biopsy at lowmagnification showing a highly cellular and poorly differentiated
tumor. (Inset) High magnification showing the spindle cell morphology.
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The actionable variants and the corresponding clinical implications are described in de-
tail for Cases 1–8 below and summarized in Tables 2 and 3, respectively. It was particularly
noticeable that the SNVs and CNAs in DDR genes provided future treatment options for four
cases (Fig. 2).
As expected, the mutation burden was found to be higher in introns than in exons
(Supplemental Fig. 1). The somatic mutations derived from theWGS data allowed mutation-
al signatures to be classified (Supplemental Table S2; Alexandrov et al. 2013a) and helped to
identify the mutational processes operative in each patient (Fig. 3).
The majority of clinically actionable variants were somatic. Targeted in silico germline
analysis of a predefined list of cancer predisposition genes (Supplemental Table S3) led to
identification of multiple germline variants of uncertain significance (data not shown). One
germline variant in RAD51B (Case 4) contributed to a homozygous impairment of a DDR lo-
cus and was therefore considered clinically actionable.
One anticipated advantage of using WGS is the ability to identify a spectrum of variants
affecting noncoding regions. We used ENCODE databases (Supplemental Table S4) to an-
notate variants in regulatory regions (Supplemental Table S5), although none was consid-
ered to be clinically actionable on the basis of current knowledge.
The results for each patient are described in more detail below.
CASE 1 (Prostate Cancer)
A 67-yr-old man with a known history of prostate cancer was referred with an unusual cuta-
neous tumor of the left thigh (Table 1). The histology of this lesion showed a dermal infiltrate
of poorly differentiated carcinoma cells (Fig. 1A) that demonstrated polyclonal prostate-spe-
cific antigen (PSA) and prostate-specific acid phosphatase (PSAP) expression by immunohis-
tochemistry (IHC). CDX2, cytokeratin (CK) 7, and CK20 markers were negative. These
findings were consistent with a prostatic origin.
The metastatic skin lesion was incompletely excised and the patient received bicalutamide
from April to November 2014 combined with radiotherapy of 20 Gy in five fractions.
Conventional androgen blockade commenced in January 2015. He received docetaxel
chemotherapy from June toNovember 2015 and enzalutamide from January to February 2016.
Table 2. Summary of clinically actionable variants
Case
Cancer
type Tier Gene
Mutation
type
VAF
(%)
Somatic/
germline
mutation Location DNA change Protein change
1 Prostate 1 SETD2 SNV 23.33 S Chr 3:47129738 NM 014159.6:
c.5143-1 G>A
PTEN CNA – S Chr 10:89590587–90376982 Loss N/A
TP53 SNV
cnLOH
36.89
–
S
S
Chr 17:7577106
Chr 17:0–13533148
NM_000546.5:
c.832C>A
Allelic Imbalance
NP_000537.3:
p.Pro278Thr
2 BRCA2 cnLOH – S Chr 13:18351244–115169878 Allelic imbalance N/A
2 Oral 1 TP53 None – N/A N/A N/A N/A
EGFR None – N/A N/A N/A N/A
2 Multiple CNA – S Complex molecular karyotype N/A N/A
DDX3X SNV 47.06 S Chr X:41198295 NM_001356.3:
c.107_108ins GC
NP_001347.3:
p.Tyr38 AlafsTer 7
3 Breast/skin 1 PIK3CA SNV 14.49 S Chr 3:178936091 NM_006218.2:
c.1633G>C
NP_006209.2:
p.Glu545Gln
(Continued on next page.)
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Table 2. (Continued )
Case
Cancer
type Tier Gene
Mutation
type
VAF
(%)
Somatic/
germline
mutation Location DNA change Protein change
TP53 Indel
Indel
cnLOH
22.32
11.76
–
S
S
S
Chr 17:7578211
Chr 17:7577085
Chr 17:1–81195210
NM_000546.5:
c.638G>A
NM_000546.5:
c.853G>A
Allelic imbalance
NP_000537.3:
p.Arg213Gln
NP_000537.3:
p.Glu285Lys N/A
N/A
2 BRCA1
BRIP1
RAD51C
RAD51D
cnLOH
cnLOH
cnLOH
cnLOH
–
–
–
–
S
S
S
S
Chr 17:1–81195210
Chr 17:1–81195210
Chr 17:1–81195210
Chr 17:1–81195210
Allelic imbalance
Allelic imbalance
Allelic imbalance
Allelic imbalance
N/A
FANCA CNA – S Chr 16:46497599–90354753 Loss N/A
4 Colorectal 1 ARID1A SNV 24.36 S Chr 1:27101198 NM 006015.4:
c.4480C>T
NP_006006.3.3:
p.Gln1494Ter
RAD51B SNV
CNA
28.57
–
GL
S
Chr 14:69061259
Chr 14:68290373–69279891
NM_133509.3.1:
c.1094C>G
Loss
NP_598193.2:
p.Pro365Arg N/A
N/A
TP53 CNA – S Chr 17:6934163–8217978 Loss N/A
2 HDAC2 CNA – S Chr 6:112939290–132327952 Loss N/A
SMAD4 SNV 8.20 S Chr 18:48604788 NM 005359.5:
c.1610A>G
NP_005350.1:
p.Asp537Gly
NFE2L2 SNV 7.52 S Chr 2:178098954 NM 006164.4:
c.91G>A
NP_6155.2:
p.Gly31Arg
5 Endometrial 1 TP53 None – S N/A N/A N/A
POLE SNV
SNV
34.07
37.50
S
S
Chr 12:133253184
Chr 12:133252045
NM_006231.2:
c.857C>G
NM_006231.2:
c.1165T>G
NP_006222.2:
p.Pro286Arg
NP_006222.2:
p.Phe389Val
Multiple SNV – S Tumor Mutation Burden Hypermutated
phenotype
N/A
6 Prostate 1 PTEN CNA – S Chr 10:85557432–105804295 Loss N/A
CDKN2A CNA – S Chr 9:10320113–26205565 Loss N/A
TP53 SNV
CNA
58.82
–
S
S
Chr 17:7573975
Chr 17:7506837–7671804
NM_000546.5:
c.1044_1051
delGGAACTCA
NP_000537.3:
p.Glu349GlyfsTer30
N/A
BRCA2 CNA – S Chr 13:32178877–33860144 Loss (homozygous) N/A
2 FANCA CNA – S Chr 16:46455960–90354753 Loss N/A
ERCC3 CNA – S Chr 2:104172062–168223828 Loss N/A
7 Sarcoma 1 NRAS SNV 96.49 S Chr 1:115256530 NM 002524.4:
c.181 C>A
NP_002515.1:
p.Gln61Lys
CDKN2A CNA – S Chr 9:21879074–22096083 Loss (homozygous) N/A
PTEN CNA – S Chr 10:42347406–135534747 Loss N/A
Multiple SNV – S Tumor Mutation Burden Hypermutated
phenotype
N/A
NF1 CNA – S Chr 17:25248166–30645676 Loss N/A
2 Multiple CNA – S Complex molecular karyotype N/A N/A
8 Soft Tissue 1 CDKN2A CNA – S Chr 9:21939408–22706613 Loss (homozygous) N/A
PTEN CNA – S Chr 10:1–135534747 Loss N/A
TSC1 CNA – S Chr 9:135377559–141213431 Loss N/A
2 BRCA2 CNA – S Chr 13:24080918–3436,992 Loss N/A
Details of the tier 1 and tier 2 clinically actionable variants identified in Cases 1–8 are presented. The term allelic imbalance was ascribed when the BAF plots
clearly revealed an acquired event, but interpretation of the Log2R plot was challenging (e.g., cnLOH vs. CN Loss). Such events were classified as “not clinically
actionable.” For cases with a hypermutated genotype (Cases 5 and 7) only clearly actionable SNVs were included.
SNV, single-nucleotide variant; indel, insertion/deletion; CNA, copy-number aberration; cnLOH, copy neutral loss of heterozygosity; SV, structural variant; S,
somatic; GL, germline.
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Table 3. Clinical significance of actionable variants
Case
Cancer
type Tier Gene
Mutation
Type
Somatic/
germline
mutation Pathway
Clinical
significance of
mutation
Potential clinical
trials
MDT decision/Impact on
clinical management
1 Prostate 1 SETD2 SNV S Chromatin
remodelling
Therapy (WEE
inhibitors)
NCT01748825 (solid
tumors)
NCT02341456 (solid
tumors)
NCT02585973 (head
and neck cancer)
Patient died before WGS
completed, but PARP/
WEE inhibitors may
have been an option.
PTEN CNA S PTEN-AKT1-
mTOR
pathway
Poor prognosis,
therapy
(mTOR, PARP
inhibitors)
NCT02145559 (solid
tumors)
NCT02465060 (NCI
match)
TP53 SNV
cnLOH
S
S
DDR
DDR
Poor prognosis,
therapy
(PARP
inhibitors)
NCT02098343
(ovarian cancer)
2 BRCA2 cnLOH S DDR Therapy (PARP
inhibitors)
NCT03040791
(DDR-impaired
prostate cancer)
NCT03012321
(DDR-impaired
prostate cancer)
2 Oral 1 TP53 None N/A N/A Therapy N/A HPV +ve indicative of
good prognosis.
Standard of care was
applied. Lack of DDR
signature (please see
text) and EGFR
mutations supported
cessation of cisplatin
and commencement of
cetuximab, respectively.
EGFR None N/A N/A
Multiple CNA S Multiple Pathological
classification
N/A
2 DDX3X SNV S RNA
metabolism
Pathological
classification,
therapy
(histone
methylation)
N/A
3 Breast/Skin 1 PIK3CA SNV S PIK3CA
signaling
Therapy (PI3K
inhibitors)
NCT02389842
(breast and solid
tumors)
NCT01226316
(breast and solid
tumors)
NCT02437318
(breast cancer)
NCT02423603
(breast cancer)
NCT01872260
(breast cancer)
NCT02088684
(breast cancer)
NCT02465060 (NCI
match)
Standard of care was
applied. Treatment with
PI3K or PARP inhibitors
proposed in event of
disease progression.
Patient died rapidly
because of disease
progression before such
therapies initiated.
TP53 SNV
SNV
cnLOH
S
S
S
DDR
DDR
DDR
Poor prognosis,
therapy
(PARP
inhibitors)
NCT02098343
(ovarian cancer)
NCT01074970
(breast cancer)
2 BRCA1
BRIP1
RAD51C
RAD51D
cnLOH
cnLOH
cnLOH
cnLOH
S
S
S
S
DDR
DDR
DDR
DDR
Therapy (PARP
inhibitors)
(Continued on next page.)
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Table 3. (Continued )
Case
Cancer
type Tier Gene
Mutation
Type
Somatic/
germline
mutation Pathway
Clinical
significance of
mutation
Potential clinical
trials
MDT decision/Impact on
clinical management
FANCA CNA S DDR Therapy (PARP
inhibitors)
NCT03012321
(Prostate cancer)
4 Colorectal 1 ARID1A SNV S Chromatin
remodelling
Therapy
(Dasatinib;
AKT inhibitor;
EZH2
inhibitor)
NCT02059265
(Ovarian cancer)
NCT02576444 (solid
tumors)
Standard of care was
applied. Excellent
response to platinum
therapy. PARP inhibition
considered as an option
at relapse.RAD51B SNV
CNA
GL
S
DDR
DDR
Therapy (PARP
inhibitors)
NCT02484404 (solid
tumors)
NCT00576654 (solid
tumors)
NCT02921256 (rectal
cancer)
TP53 CNA S DDR Poor prognosis,
therapy
(PARP
inhibitors)
NCT02098343
(ovarian cancer)
2 HDAC2 CNA S DDR Therapy (PARP
inhibitors)
NCT03012321
(prostate cancer)
SMAD4 SNV S TGF-β signaling Biological
mechanism
N/A
NFE2L2 SNV S Antioxidant
metabolism
Biological
mechanism
N/A
5 Endometrial 1 TP53 None S DDR Pathological
classification
N/A Results from WGS clarified
histopathological
classification, confirming
an endometrioid rather
than serous tumor type
with good prognosis.
Patient declined
chemotherapy on basis
of confirmatory
prognostic information
from WGS. Option of
checkpoint inhibitors in
event of disease
progression.
POLE SNV S Polymerase
proofreading
Polymerase
proofreading
Therapy (anti-
PDL1)
NCT02912572
(endometrial
cancer)
Multiple SNV S Multiple Therapy (anti-
PDL1)
NCT02912572
(endometrial
cancer)
6 Prostate 1 PTEN CNA S PTEN-AKT1-
mTOR
pathway
Poor prognosis,
therapy
(mTOR
inhibitors)
NCT02145559 (solid
tumors)
NCT02465060
(NCI Match)
Commenced treatment
with PARP inhibitor
rucaparib 24 months
ago following results
from WGS. Still alive.
Clinical trial of anti-PD1
inhibitor might also be
considered.
CDKN2A CNA S Cell cycle
regulator of
P53
Therapy (Aurora
/VEGF
inhibitors)
NCT02478320 (solid
tumors)
TP53 SNV
CNA
S
S
DDR
DDR
Poor prognosis,
therapy
(PARP
inhibitors)
NCT03040791
(DDR-impaired
prostate cancer)
NCT03012321
(DDR-impaired
prostate cancer)
BRCA2 CNA S DDR Therapy (PARP
inhibitors)
NCT03040791
(DDR-impaired
prostate cancer)
NCT03012321
(Continued on next page.)
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Table 3. (Continued )
Case
Cancer
type Tier Gene
Mutation
Type
Somatic/
germline
mutation Pathway
Clinical
significance of
mutation
Potential clinical
trials
MDT decision/Impact on
clinical management
(DDR-impaired
prostate cancer)
2 FANCA CNA S DDR Therapy (PARP
inhibitors)
NCT03040791
(DDR-impaired
prostate cancer)
NCT03012321
(DDR-impaired
prostate cancer)
ERCC3 CNA S DDR Therapy (PARP
inhibitors)
NCT03040791
(DDR-impaired
prostate cancer)
NCT03012321
(DDR-impaired
prostate cancer)
7 Sarcoma 1 NRAS SNV S RAS pathway Therapy (Solid tumors and
myeloma)
NCT01449058
(Solid tumors and
hematology)
NCT01763164
(melanoma)
NCT02465060
(NCI match)
Patient died before WGS
completed. Px had
shown lack of reponse
to anti-NCT02407509
EGFR antibody therapy
MEK inhibitors.
CDKN2A CNA S Cell cycle
regulator of
P53
Therapy
(Aurora/VEGF
inhibitors
NCT02478320
(solid tumors)
PTEN CNA S PTEN-AKT1-
mTOR
pathway
Therapy (mTOR
inhibitors)
NCT02145559
(solid tumors)
NCT02465060
(NCI match)
Multiple SNV S Multiple Therapy (anti-
PDL1)
NCT02912572
(endometrial
cancer)
NF1 CNA S RAS pathway Therapy (MEK
inhibitor)
NCT02465060
(NCI match)
2 Multiple CNA S Multiple Poor prognosis N/A
8 Soft tissue 1 CDKN2A CNA S Cell cycle
regulator of
P53
Therapy
(Aurora/VEGF
inhibitors)
NCT02478320
(solid tumors)
MDT recommendation of
mTOR inhibition
declined by clinician.
Patient being prepared
for surgical resection on
disease progression.
PTEN CNA S PTEN-AKT1-
mTOR
pathway
Therapy (mTOR
inhibitors)
NCT02145559
TSC1 CNA S PTEN-AKT1-
mTOR
pathway
Therapy (mTOR
inhibitors
PARP
inhibitors)
NCT02201212
(solid tumors)
NCT02352844
(solid tumors)
NCT02576444
(solid tumors)
2 BRCA2 CNA S DDR Therapy (PARP
inhibitors)
NCT02465060
(NCI match)
The potential clinical implications of the tier 1 and tier 2 variants described in Table 2 are shown, including impact of the variant on diagnosis, prognosis,
potential treatment, or clinical trials for which the patient might be eligible. Specifically, for defects in the DDR pathway, only inferred homozygous mutations
were classified as clinically actionable (highlighted by shaded background).
SNV, single-nucleotide variant; CNA, copy number aberration; cnLOH, copy neutral loss of heterozygosity; SV, structural variant; DDR, DNA damage response; S,
somatic; GL, germline.
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TGS of DNA derived from the metastasis showed a variant in TP53 (c.832C>A,
p.Pro278Thr), indicative of poor prognosis. WGS of paired tumor and germline DNA con-
firmed the somatic tier 1 SNV in TP53 and additionally revealed a cnLOH region of
Chromosome 17 (17p13.3-p12) involving TP53, as well as copy-number loss of PTEN and
allelic imbalance of BRCA2 (Table 2; Fig. 2), all genes involved in the DDR. These events pre-
sented with allelic imbalance, which was most likely explained by germline contamination as
the tumor content for biopsied tissue was estimated as 50% (Table 2; Supplemental Fig. S2).
Mutation signature 5 associated with all cancer types (Alexandrov et al. 2013a) was the dom-
inant signature from WGS data (Fig. 3). WGS also showed a SETD2 (tier 1) variant (c.5143-
1G>A) (Table 2). Unfortunately, the patient died of progressive disease before the results
of WGS were available.
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Figure 2. Identification of somatic and germline variants in genes from the DNA damage response (DDR)
pathway fromCases 1–8. Graphical representation of the variants identified byWGS in 22 DDR pathway genes
in cancer Cases 1–8. A and B show somatic and germline variants, respectively, for each cancer case. Each bar
or track on the horizontal axis represents a different cancer case and the 22 individual DDR genes are repre-
sented on the vertical axis. CNAs, indels, and SNVs are represented by circles, squares, and diamonds, respec-
tively. The color key indicates more detail about the type of variant (e.g., a red circle represents a homozygous
copy-number loss). Only disruptive somatic or germline SNVs and indels are included, whereas for germline
variants (B) only SNVs with minor allele frequency of <6% are included. Case 1 includes a somatic missense
SNV and a cnLOH region involving TP53, as well as copy-number loss of PTEN and allelic imbalance of
BRCA2. Case 2 presents copy-number aberrations overlapping various DDR genes, but no SNVs, indels, or
copy-number events involving TP53. Case 3 includes TP53 mutations, an allelic imbalance involving TP53,
BRCA1, BRIP1, RAD51C, and RAD51D, and a single loss involving FANCA. In Case 4, WGS detected a germ-
line deleterious SNV in RAD51B, together with a somatic CN loss in the same locus. Case 5 includes somatic
mutations in various DDR genes but no copy-number aberrations, whereas RAD54L and ATM in the germline
are affected by a region of homozygosity and a missense mutation, respectively. Case 6 has a frameshift mu-
tation and aCN loss involving TP53 and, importantly, a somatic homozygousCN loss encompassingBRCA2. In
Case 7, most DDR genes are affected by a somatic CN loss or gain, whereas the germline includes missense
mutations in FANCI, RAD54L, RAD51B, and PARP1. Finally, in Case 8, PTEN and BRCA2 are affected by
somatic CN losses, andATM includes a splice site mutation in the germline. See themain text for more details.
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CASE 2 (Head and Neck Cancer)
A 57-yr-old man presented with a large, left-sided base of tongue tumor and lymphadenop-
athy (Table 1). Biopsy from the oropharyngeal lesion revealed a nonkeratinizing squamous
cell carcinoma (Fig. 1B). The tumor demonstrated positive staining with p16 IHC tests, in
keeping with human papilloma virus (HPV) etiology and associated with a good prognosis
for oropharyngeal cancer (Langendijk and Psyrri 2010).
SNV and CNA analyses of WGS data did not show any somatically acquired clinically ac-
tionable mutations (Table 2). The genome exhibited a complex karyotype, a mutation in
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Figure 3. The proportion of mutation signatures in Cases 1–8. Mutation signatures were obtained from the
COSMIC mutation signatures consensus database (http://cancer.sanger.ac.uk/COSMIC /signatures), which
were derived using publishedmethods developed by Alexandrov et al. (2013a). Signatures represent genomic
SNV distribution in a trinucleotide context. The contributions of each COSMIC signature found in the data
were calculated using the deconstructSigs package (Rosenthal et al. 2016) in R. Stacked bars represent the pro-
portion of each mutation signature found in each case across the whole genome, where all signatures found
per case sum to 1. Mutation signature 1 is the most ubiquitous and represents aging. Signature 2: AID/
APOBEC association. Signature 3: BRC1/2-associated and DNA double-strand break repair defect.
Signature 4: smoking. Signature 5: unknown etiology. Signature 6: DNA mismatch repair defect. Signature
7: UV exposure. Signature 8: unknown. Signature 9: polymerase-associated mutation pattern. Signature 10:
associated with altered POLE activity. Signature 11: alkylating agents. Signature 12: unknown. Signature 13:
AID/APOBEC association. Signature 14: unknown. Signature 15: DNA mismatch repair defect. Signatures
16, 17, 18, 19: unknown. Signature 20: DNA mismatch repair defect. Signature 21: unknown. Signature 22:
exposure to aristolochic acid. Signature 23. Unknown. Signature 24: exposure to aflatoxin. Signature 25: un-
known. Signature 26: DNAmismatch repair defect. Signature 27,28: unknown. Signature 29: tobacco chewing.
Signature 30: unknown. More details of signatures are described in Supplemental Table S2.
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DDX3X, and absence of TP53mutations, all in keeping with HPV-positive squamous cell car-
cinoma (Seiwert et al. 2015). We confirmed the presence of HPV-derived sequences in the
whole-genome data and identified the viral subtype (Table 3; Supplemental Materials and
Methods). Presence of mutation signature 2 is consistent with the viral etiology of the tumor
(Fig. 3).
The patient started radical chemoradiotherapy at 65 Gy in 30 fractions in August 2016.
Following one cycle of cisplatin, he developed intractable tinnitus. Cisplatin was stopped,
a decision supported by the absence of a DDR mutation signature and good prognosis fea-
tures, and the patient was started on concomitant cetuximab (Table 3). Reassuringly, WGS
confirmed that there were no EGFR resistance mutations to this drug. Positron-emission
and computed tomography (PET-CT) imaging at 3 mo indicated no residual disease.
In this case, WGS did not demonstrate any actionable mutations. However, it confirmed
the presence of HPV, which, combined with absence of TP53 mutations, indicated a good
prognosis for this patient. The absence of biallelic mutations in DDR genes or in the known
cancer predisposition gene EGFR assisted in managing drug side effects and in confirming
the choice of an alternative targeted therapy (Iida et al. 2014; Tajima and Koda 2015).
CASE 3 (Breast Cancer and Melanoma)
A 42-yr-old man with a previous history of malignant melanoma presented with a left chest
wall mass and widespread lymphadenopathy (Table 1). Combined PET-CT scanning re-
vealed disseminated disease with bony involvement. Biopsies from the chest wall lesion
and overlying skin revealed a malignant tumor with an epithelioid morphology infiltrating
into skeletal muscle. A bone marrow trephine biopsy (Fig. 1C) also revealed marrow space
involvement. The tumor cells were immune-reactive for nonspecific epithelial markers
(CAM 5.2, AE1/AE3) as well as CK7, CK19, GATA3, and GCDFP, suggesting a breast origin.
The tumor did not express CK20 or CDX2 (colorectal), PSA, RCC (renal), TTF1 (lung), or mel-
anoma markers. The suspicion was that it was of breast origin but ductal carcinoma in situ
(DCIS) could not be identified in the chest wall biopsies, and a sweat gland tumor could
not be excluded. Estrogen receptor (ER), progesterone receptor (PR), and Her-2/neu
(ErbB-2) hormone markers were also negative by IHC tests. Based on these findings, the dif-
ferential diagnosis was either a triple-negative breast (ductal) carcinoma or a malignant skin
adnexal tumor. The patient commenced treatment with a standard carcinoma of unknown
primary (CUP) schedule with six cycles of ECX (epirubicin, cisplatin, capecitabine/Xeloda)
and showed a good clinical and radiological response. However, 3 mo later, when there
was evidence of progressive chest wall disease, the patient entered a Phase II clinical trial
of immunotherapy against standard of care chemotherapy. He was randomized to the con-
trol arm and received eribulin, a potent mitotic inhibitor. His disease rapidly progressed,
leading to a switch to paclitaxel and bicalutamide because of strong androgen receptor ex-
pression identified by IHC tests. He achieved a complete clinical and radiological remission
in the known sites of disease within 3 mo.
Because TGS and WGS showed an activating PIK3CA mutation (c.1633C>G,
p.Glu545Gln), the proposed management was to proceed with the PIK3CA inhibitors, tase-
lisib or pictilisib, at disease progression (Turner et al. 2015). In addition, WGS revealed two
different acquired pathogenic TP53mutations and an allelic imbalance reflecting either a CN
loss or cnLOH involving TP53, BRCA1, BRIP1, RAD51C, and RAD51D (Fig. 2A) and a single
loss of FANCA indicating PARP inhibition as a potential therapeutic avenue. Consistent with
this, we identified mutation signature 3 (Fig. 3).
Similar to Case 1, this case illustrates that WGS can reveal all types of mutations in the
DDR pathway. The dominant mutation signatures in this patient were signatures 16 (un-
known significance), 2, and 13, whereas the DDR signature was also present. A germline
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deletion polymorphism involving APOBEC3A and APOBEC3B on Chromosome 22 is asso-
ciated with the presence of large numbers of signature 2 and 13 mutations and with predis-
position to breast cancer (Nik-Zainal et al. 2014), but this patient did not carry the germline
polymorphism.
CASE 4 (Colorectal Cancer)
A 64-yr-old woman who presented with abdominal pain underwent excision of a radiolog-
ically nonsuspicious simple cyst of the right ovary (Table 1). At operation both ovaries were
found to be infiltrated by solid tumor, there was a dilated right fallopian tube, and numerous
widespread peritoneal deposits were observed. A bilateral salpingo-oophorectomy (BSO)
was performed and the peritoneal lesions were biopsied. Histology of the ovaries and peri-
toneal lesions revealed a poorly differentiated carcinoma with areas of glandular and signet
ring cell morphology, as well as focal neuroendocrine differentiation. The right fallopian
tube was infiltrated by malignant cells and contained foci of endometriosis. The tumor cells
were immune-reactive for carcinoembryonic antigen (CEA), CDX2, CK20, CK8/18, and
CA19.9 IHC tests, suggesting a colorectal origin, and tested negative for markers of gyne-
cological, breast, or other common tumors of epithelial origin (CK7, CA125, inhibin, p16,
p53, WT1, PAX8, GCDPF, ER, and PR). Cytology of peritoneal washings also showed a ma-
lignant population of epithelial cells. The findings were consistent with a metastatic carcino-
ma of gastrointestinal (GI) origin. Endoscopic examination of the lower GI tract was carried
out and revealed a tumor in the cecum at the appendiceal orifice. Biopsies from this area
(Fig. 1D) revealed similar histological findings with tumor appearing to arise from overlying
dysplastic mucosa. The overall findings were consistent with metastatic adenocarcinoma of
colorectal origin. The patient underwent right hemicolectomy and hysterectomy. The sur-
gery left her free of visible disease and she then opted for oxaliplatin-based adjuvant
chemotherapy.
TGS did not reveal any clinically actionable mutations. WGS identified a tier 1 germline
deleterious SNV in RAD51B together with an acquired CN loss of this locus that could be
regarded as a second hit and is consistent with impairment of the DDR signaling pathway
function (Fig. 2A,B). Supporting these findings, mutation signature 3 was clearly present in
this tumor (Fig. 3). Furthermore, WGS showed a tier 1 nonsense mutation in ARID1A
(c.4480C>T, p.Gln1494Ter). A recent study demonstrated synthetic lethality by targeting
EZH2 histonemethyltransferase activity inARID1A-mutated tumors using a clinically applica-
ble small molecule inhibitor (Bitler et al. 2015a), and a clinical trial for patients with mutations
in ARID1A is now recruiting and others are planned (Bitler et al. 2015b) for which the patient
could be eligible.
WGS also revealed tier 2 mutations in HDAC2, NFE2L2, and SMAD4 that are likely to
have biological and prognostic significance (Table 2) but are not clinically actionable.
Importantly, this case illustrates impairment of the DDR pathway because of a combina-
tion of a germline deleterious SNV with a second acquired hit affecting RAD51B. The patient
may benefit from PARP-1 inhibition should she relapse after standard care. WGS, but not
TGS, also revealed a tier 1 defect in the key chromatin-remodeling geneARID1A, supporting
eligibility to potentially efficacious therapy as part of a clinical trial.
CASE 5 (Endometrial Cancer)
A 55-yr-old woman presented with postmenopausal bleeding (Table 1). Ultrasound imaging
of the pelvis revealed a uterine mass. Histolopathological review of the biopsy suggested a
grade 3 mixed endometrioid/serous endometrial carcinoma. Total laparoscopic hysterecto-
my and bilateral salphingo-ophorectomy demonstrated a polypoidal tumor in the uterine
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cavity arising from the endometrium and extending to the lower segment. The results of his-
topathological analysis of the resected specimen (Fig. 1E) were similar to that of the biopsy.
IHC tests were difficult to interpret; ER, PAX8, and vimentin showed positivity in some areas
of the tumor (in keeping with endometrioid carcinoma) but occasional foci showed strong
diffuse p16 staining (usually seen in serous carcinoma). PR (endometrioid) and WT1 (serous)
markers were negative. The pattern of expression was therefore mixed (Kaspar and Crum
2015). This diagnostic uncertainty was highly clinically relevant, as uterine serous carcinoma
is an aggressive tumor that is typically managed with intensive adjuvant therapy, whereas
endometrioid histologies are associated with a more benign course. As uterine serous car-
cinoma is frequently associated with the presence of TP53 mutations, molecular testing
was performed to identify these and other variants useful in guiding management (SGO
Clinical Practice Endometrial Cancer Working Group et al. 2014a,b). Interestingly, although
neither TGS nor WGS detected any TP53 mutation, WGS demonstrated a pathogenic mu-
tation in the exonuclease domain of the replicative DNA polymerase POLE (c.857C>G,
p.Pro286Arg) (Table 2), along with the characteristic ultramutated phenotype (Supplemental
Fig. S1) and dominant mutational signature 10 this causes (Fig. 3; Prindle et al. 2010;
Church et al. 2014; van Gool et al. 2015). Although unexpected, this result was not entirely
surprising, as POLE mutations are often associated with high tumor grade and difficulty in
pathological classification (Hussein et al. 2015; van Gool et al. 2018). Despite this
association, endometrial cancers carrying POLE exonuclease domain mutations are recog-
nized to have an excellent prognosis, possibly because they are more immunogenic
than other cancers (Van Gool et al. 2015). In light of the molecular data, the initial patholog-
ical impression of an aggressive serous carcinoma was revised to a much more favorable
prognosis (Tashiro et al. 1997; Bansal et al. 2009; Yemelyanova et al. 2011; Church et al.
2014; Stelloo et al. 2015). The patient elected to have post-operative brachytherapy only,
and did not receive the adjuvant chemotherapy and external beam radiotherapy that is
the standard of care for uterine serous carcinoma. This case illustrates that WGS results
can assist with clinically relevant pathological differential diagnosis and can support de-
escalation of therapy in line with the patient’s choice (Table 3). Moreover, in the event of
disease progression, POLE mutations may predict sensitivity to nivolumab or pebrolizu-
mab (Santin et al. 2016).
CASE 6 (Prostate Cancer)
A 63-yr-old man presented with a PSA of 2900 µg/ml and was found to have a Gleeson 4+4
prostatic adenocarcinoma on biopsy (Table 1). Clinical imaging revealed pulmonary and
bony metastases. Despite androgen deprivation treatment, the patient progressed and
there was no response to docetaxel or radiotherapy. A biopsy from a rib metastasis at this
time showed neuroendocrine differentiation (Fig. 1F), and it was concluded that a small-
cell carcinoma component had developed following treatment (Miyoshi et al. 2001;
Lipianskaya et al. 2014; Nadal et al. 2014).
TGS performed onDNA obtained from the ribmetastasis showed a pathogenicmutation
in TP53. WGS confirmed the mutation and also showed a CN loss involving TP53 and, im-
portantly, an acquired homozygous CN loss encompassing BRCA2 (Table 2; Fig. 2A). The
patient had a dramatic clinical, radiological, and biochemical response following plati-
num-based chemotherapy (etoposide and carboplatin). At biochemical relapse, he obtained
compassionate access to the PARP inhibitor rucaparib on the basis of the results from WGS
showing a DDR pathway defect supported by the presence of mutation signature 3 (Fig. 3).
He is alive 2 years following diagnosis of metastatic disease. WGS also showed loss of PTEN
and CDKN2A. These offer further options for future therapeutic intervention with mTOR in-
hibitors and Aurora/VEGF inhibitors, respectively.
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This case illustrates thatWGS can reveal acquired alterations in DDR genes, including ho-
mozygous deletions and deleterious SNVs, leading to therapeutic intervention.
CASE 7 (Sarcoma)
A 42-yr-old man presented with a soft tissue mass in the right axilla, and a biopsy of this
showed a high-grade malignant tumor with a mostly epithelioid appearance (Fig. 1G) and
extensive necrosis (Table 1). The initial diagnosis made by the referring center was that of
a cancer of unknown primary, but the possibility of a dedifferentiated metastatic malignant
melanoma or sarcoma was raised at the time. The patient commenced conventional chemo-
therapy. Following transfer of care to a specialist orthopedic center, histology review noted
focal spindle cell areas and suggested amesenchymal tumor origin. The tumor was immune-
reactive for S100 (nerve sheath marker) and INI1, focally positive for desmin and myogenin,
and in some areas around necrotic foci, HIF1-α-positive (seen in neurofibromatosis 1). The
tumor cells did not express CD45 (hematological), Melan A or HMB45 (differentiated mela-
noma markers), CD117 (GIST, dermatofibroma, angiosarcoma, Ewing’s sarcoma), or phos-
phor-MET. FISH for the SS18 fusion gene (synovial sarcoma) was negative. The overall
histopathological findings weremost consistent with a malignant peripheral nerve sheath tu-
mor (MPNST), showing rhabdomyosarcomatous differentiation (Triton tumor) as shown by
desmin and myogenin immunopositivity. The absence of expression of H3K27me3 was
also supportive of a histological diagnosis of MPNST (Lee et al. 2014; Prieto-Granada
et al. 2016). An epithelioid MPNST was considered but thought to be unlikely because of
INI1 IHC positivity. Furthermore, no CNA or cnLOH regions involving SMARCB1 were iden-
tified for this patient and no other inactivating mutations.
Shortly after initial presentation the patient developed metastatic disease in the left
thigh. A biopsy showed similar histological findings and was subjected to WGS. TGS and
WGS revealed a tier 1 mutation in NRAS (c.181C>A, p.Gln61Lys), which indicates lack of re-
sponse to anti-EGFR antibody therapy or BRAF inhibition and points to MEK-inhibitor ther-
apy. Similar to Case 5, WGS revealed a high number of SNVs/indels consistent with a
hypermutator genotype (Supplemental Fig. S1); therefore, SNV analysis presented is limited
to Tier 1 findings only.
No translocationevents typical of sarcomawere identified.However,WGSshowedacom-
plex karyotype including an acquired homozygous CN loss of CDKN2A (Aurora/VEGF inhib-
itors), loss ofPTEN (mTOR inhibitors), and a somatically acquired loss ofNF1, again indicating
potential response toMEK inhibition.CDKN2A loss is a common event in cancer, and there is
preclinical evidence for efficacy of CDK4/6 inhibitors in tumors with CDKN2A loss (Gao et al.
2015; Elvin et al. 2017). Interestingly, in a phase 1 trial of abemaciclib, a selective CDK4 and 6
inhibitor, a patient with metastatic melanoma achieved a PR carrying similar molecular alter-
ations (NRASmutation and copy-number loss at the INK4 locus) toCase7 (Patnaik et al. 2016).
Surprisingly, the mutation signature strongly implied UV-light exposure (Fig. 3) as the un-
derlying mutagenic mechanism, raising the possibility that the original suspected diagnosis
of a dedifferentiated malignant melanoma was correct.
WGS of the germline of this patient revealed no mutation inNF1. Genes related to PRC2
components were also investigated. For SUZ12, Case 7 showed an acquired CN loss (Chr
17:25,248,166–30,645,676) and for both EZH1 and EZH2, acquired subclonal CN losses
were observed (Chr 7:98,693,981–159,138,663 and Chr 17:30,645,677–81,195,210, respec-
tively). No CNAs or cnLOH events involving EED were identified. This madeMPNST unlikely
and highlights that the absence of H3K27me3 expression is not specific for this tumor type.
Shortly after submission of the sample for WGS, the patient developed widespread me-
tastases and died. This case illustrates that even with extensive profiling, it is not always pos-
sible to provide a definite diagnosis.
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CASE 8 (Soft Tissue Tumor)
A 7-yr-old boy presented with neck pain due to a soft tissue mass causing subluxation at
the C4/C5 vertebral level. Histology of the mass (Fig. 1H) showed a cellular spindle cell
lesion with focal nuclear atypia (Table 1). The tumor cells were immune-reactive for
smooth muscle actin, but other soft tissue markers were negative. The proliferation index
by Ki67 was 5%, indicative of a low-grade lesion. FISH showed no evidence of common
translocation events including SS18, EWSR1, and MDM2, and there was no amplification
by real-time PCR for the sarcoma-associated fusion genes ETV6-NTRK3 and SS18-SSX1/2/
4. Taken together, these findings were not sufficient for a definitive diagnosis. The differ-
ential diagnosis included infantile myofibroma, myofibrosarcoma, and a low-grade spindle
cell sarcoma. At the time of sequencing, histology and initial results of molecular genetic
tests, taken together with imaging and clinical context, were consistent with a low-grade
sarcoma, not otherwise specified (NOS). WGS analysis did not reveal any sarcoma-associ-
ated translocations. There were no clearly pathogenic SNVs, and the mutational burden of
the tumor was low (Supplemental Fig. 1). There was an acquired homozygous loss of
CDKN2A and heterozygous acquired losses of PTEN, TSC1, and BRCA2 (Table 2). The
Cancer Genomics MDT recommended mTOR inhibition with temsirolimus, PARP inhibi-
tion, or aurora/VEGF inhibitors as potential treatment options as there was no standard
of care for this patient.
The patient was subsequently offered conventional empirical chemotherapy at the local
center (doxorubicin, ifosfamide, etoposide) followed by surgical resection when imaging
postchemotherapy showed marked tumor progression despite concerns regarding positive
resection margins and associated morbidity and risks. This case highlights the reluctance to
use information fromWGS for clinical decision-making even in a palliative setting and in sit-
uations where there is no standard of care.
WGS versus In Silico WES: Clinical Implications
In summary, WGS led to identification of clinically actionable SNVs and CNAs for each case.
Although exome sequencing can theoretically identify many of these changes, there are lim-
itations to this approach. To explore whether the same results could have been obtained
fromWES, we applied an in silico filter to our WGS data using the SureSelect target regions
and compared results obtained by the two different methods.
All clinically actionable SNVs detected by WGS in the eight patients were also detected
when applying the in silico SureSelect filter on our data. However, for seven of the genes with
actionable mutations in our cohort, 14 exons were not covered (Supplemental Table S6).
Moreover, the SureSelect panel did not include 152 genes listed in the COSMIC Cancer
Driver Gene List (Supplemental Table S7), and a further 2038 exons from remaining
COSMIC genes are also not included in the panel (Supplemental Table S8). Furthermore,
it is now well established that WES results will depend on the efficacy of capture and may
miss up to 20% of targets. Unfortunately, it is not possible to predict which exonic regions
these might be and therefore we could not simulate this in our analysis (Bamshad et al.
2011; Wang et al. 2017). For WGS of each cancer case, the average coverage across the en-
tire genome is shown in Supplemental Table S9 and the percentage of COSMIC genes cov-
ered at ×75, averaged over the eight cancer cases in Supplemental Table S10.
For CNA and cnLOH events, we did not identify any differences that would affect the clin-
ically actionable findings for the patients presented. However, we did identify events affect-
ing noncoding regions that demonstrate the potential advantages of WGS over WES. These
included (a) intergenic and intronic copy-number losses, (b) intergenic and intronic break-
points, and (c) altered levels of allelic imbalance that would have been missed by WES
(Supplemental Fig. S3).
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For mutation analysis, we compared trinucleotide counts in our data to signatures from
the COSMIC database (Supplemental Tables 11, 12 for WGS and WES, respectively).
These signatures are based on whole-genome studies and are applicable to biological pro-
cesses that affect the whole genome such as UV damage and smoking. Thus, the whole-ge-
nome data are more reflective of the true mutation signatures because we have more
mutations and, therefore, more data to consider. We performed the signature analysis on re-
gions defined by the SureSelect panel covering the whole exome and found that unless the
samples contained an unusually large number of mutations (Cases 5 and 7) the signatures are
not consistent with the WGS (Supplemental Fig. S4). We found that Case 5 is the only case
with identical signatures in WGS and WES, though Cases 2 and 7 are similar.
DISCUSSION
To our knowledge, this is the first study to evaluate the potential clinical utility of WGS in
management of a consecutive series of patients with advanced cancer of varying tissue or-
igin. Strikingly, for the first eight patients recruited and described here, WGS led to the iden-
tification of clinically actionable changes in all eight cases. WGS results helped to clarify an
uncertain histopathological diagnosis in one case (Case 5), raised the possibility of an alter-
native diagnosis in a second case (Case 7), informed or supported prognosis in two cases
(Cases 2 and 5), directly informed treatment changes in three patients (Cases 2, 5, and 6),
leading to the joint clinicians’ and patients’ decision to de-escalate therapy in one case
(Case 2), and indicated potential treatment options in all eight cases. Overall 26 different
tier 1 clinically actionable somatic findings were identified from WGS compared with six
SNVs/indels using the routine TGS approach. These provide exemplars of all of the five dif-
ferent analysis approaches described in the Introduction.
In fourpatients (Cases1,3, 4, and6)WGSrevealeda likelybiallelicDDRmutationsignature
thatwouldhavebeenmissedby conventional targetedcancerpanel approaches, as itwasde-
fined by integration of SNVs, indels, and copy-number losses and analysis of global mutation
signatures. These were in very different tumor types (prostate, male breast, and colorectal),
yet all would be amenable to pharmacological intervention. Indeed, one patient (Case 6) ob-
tained compassionate access to a PARP inhibitor and remains in remission at 24 mo.
Mutation burden is an important indicator of prognosis and indicates patients suitable for
treatment with checkpoint inhibitors. In our study, a patient with endometrial cancer (Case 5)
showed ultramutation because of a somatic POLE exonuclease domain mutation, findings
associated with excellent prognosis of endometrial cancers, and the patient therefore opted
to decline chemotherapy, thereby avoiding the associated toxicity (van Gool et al. 2016).
Treatment with checkpoint inhibitors remains an option for this patient should she show clin-
ical signs of relapse.
In contrast to conventional TGS, WGS provides information on both somatic and germ-
line variants. This is important, as the same genes may underpin acquired or inherited can-
cers. For example, we identified acquired copy-number changes in BRCA1/2 that enabled
synthetic lethal drugs to be used. Similarly, mutations in POLE were originally identified in
inherited colorectal cancers but have since been recognized as somatic changes in both co-
lorectal and endometrial cancers. Finally, Case 4 carried a deleterious germline variant in
RAD51B and acquired loss of the other allele in the tumor. This information might be impor-
tant for informing families of the genetic risk of cancer (Briggs and Tomlinson 2013) and also
to pinpoint a homozygous impairment of the DDR pathway.
Several cancers are known to be associated with viruses (Martin andGutkind 2008). In our
series, Case 2 (oropharyngeal cancer) had an HPV etiology indicated by p16 immunohisto-
chemistry (a surrogate marker for HPV infection), which indicates a better prognosis than
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HPV-negative or smoking-related oral tumors (Duncan et al. 2013). IHC testing, however, has
limitations, including a significant false-positive rate, and does not indicate viral subtype.
WGS provided direct confirmation of the virus presence, as well as the subtype (Mahajan
2016). This is important as clinical trials relating to de-escalation of therapy in patients
with good prognosis are underway. In addition to confirming the HPV status, WGS also in-
formed the management of side effects leading to de-escalation and the choice of alterna-
tive therapy by confirming lack of DDR mutations and absence of EGFR mutations, which
would have conferred resistance to cetuximab.
We did not find any clinically actionable mutations in noncoding regions or actionable
translocations. Evidence of the clinical actionability of these types of events in solid tumors
remains limited. For noncoding regions, mutations in the promoter of TERT2 gene are well-
described (Huang et al. 2013), but these did not occur in our cohort. Clinically actionable or
recurrent translocations have been described in lung and prostate cancer but were absent in
our patients. Interestingly, sarcomas are characterized by frequent translocation events.
However, the patient in our cohort who was referred with a possible sarcoma diagnosis
but was found to have a UV light signature also did not carry any sarcoma-associated trans-
locations, further strengthening the possibility that the primary tumor was not a sarcoma.
The turnaround time of WGS for cancer patients is critical. Two of the patients (Cases 1
and 7) died beforeWGS could be completed. Referral of patients forWGS should be encour-
aged at earlier stages in the disease course. Our fastest turnaround time for the whole pro-
cess (including pathological assessment, release of tissue blocks, sequencing, and analysis
stages) was 3 wk.
In theUnitedKingdom’sNationalHealth Service (NHS),wewere limitedby the availability
of established funded therapies. Two treatment regimens emerge from this study as being of
particular importance: PARP inhibitors for patientswith defects in theDDRpathwayand PDL1
checkpoint inhibitors forcancers showinghypermutation.Theseweremadeavailable through
clinical trials or compassionate use. Clearly, this limited pilot study does not allow any conclu-
sions regarding improvement in clinical outcome of patients undergoing the precision med-
icine approach presented herein. The challenges of testing physicians’ choice versus
molecularly directed therapy in a randomized clinical trial setting highlightedby the SHIVA tri-
al (Le Tourneau et al. 2015). Since then,major efforts using extensive targeted sequencing ef-
forts systematicallyon thousandsofpatientswithadvancedcancerhavedemonstratedclinical
utility in 35% of patients. Other similar studies have been initiated (Zehir et al. 2017).
Nonetheless, the results of this initial pilot study demonstrate that WGS can have an im-
pact on informing diagnosis, prognosis, and potential treatment choice, including access to
clinical trials, and justifies the systematic evaluation of the clinical utility of WGS in the man-
agement of patients with cancer in larger cohorts of patients.
METHODS
Patients and Ethics
The first eight patients referred consecutively to the study are described (i.e., there was no
preselection of cases). Patients were consented for analysis of tumor and constitutional
DNA and feedback of somatic genetic testing results by a clinician. Feedback of clinically ac-
tionable germline variants was optional. Details of ethical approval are highlighted below.
Sample Preparation and DNA Extraction
Tumor Tissue Handling
All patients underwent biopsy of primary and/or metastatic cancer to obtain fresh tissue for
sequencing. Fresh tissue samples were collected either by the clinician at the time of biopsy
Clinical WGS in cancer
C O L D S P R I N G H A R B O R
Molecular Case Studies
Schuh et al. 2018 Cold Spring Harb Mol Case Stud 4: a002279 20 of 27
 Cold Spring Harbor Laboratory Press on January 30, 2020 - Published by molecularcasestudies.cshlp.orgDownloaded from 
or from the resection specimen by the pathologist at dissection. Samples were snap-frozen in
liquid nitrogen and an H&E frozen histology section was taken to confirm tissue content.
Only samples with microscopically estimated tumor cell content of >40% were used for se-
quencing. Further formalin-fixed, paraffin-embedded (FFPE) tissue samples were collected
for routine diagnostic histopathology, applying standard processing protocols such as
H&E staining and IHC as appropriate. Frozen tissue was thawed rapidly for nucleic acid ex-
traction. All samples underwent targeted sequencing using the 46 Gene Cancer Panel (as
described in Hamblin et al. 2017) and WGS (methods described below and in
Supplemental Information).
DNA Extraction
Constitutional DNAwas isolated from 1.5 ml peripheral blood using the QIASymphony DSP
DNAMidi kit (QIAGEN), according to the manufacturer’s protocol. Tumor DNA was extract-
ed from fresh frozen tissue using the All PrepMini DNAExtraction kit (QIAGEN), as described
in the manufacturer’s protocol.
Whole-Genome Sequencing
Libraries of 350-bp fragments were generated from 1 µg sheared genomic DNA using the
TruSeq PCR-Free library preparation kit (Illumina). Of note, 2 × 126 paired-end sequencing
was performed using the HiSeq2500 HTv4 (Illumina). WGS was performed at a planned cov-
erage of 30× for the constitutional DNA and of 75× for the tumor. The average coverage
data across the entire genome per case, expressed as average number of reads, is shown
in Supplemental Table 9 and the percentage of the genes covered at 75×, averaged over
the eight tumor samples tested, in Supplemental Table 10.
Data Analysis
For a detailed description of alignment to the human reference genome, SNV, and structural
variant calling, calculations of absolute exonic and intronicmutation burden, identification of
previously described mutation signatures (Alexandrov et al. 2013a), the calculations of
COSMIC signatures (Rosenthal et al. 2016), annotations of coding and noncoding variants,
and detection of viral sequences, please refer to the Supplemental Materials and Methods.
Briefly, analysis was performed using a bespoke, locked-down, and version-controlled
bioinformatics pipeline according to the required specification for clinically accredited
laboratories.
Paired-end alignment of sequencing data against the reference genome hg19 (GRCh 37)
was performed using the Whole-Genome Sequencing Application v2.0, based on Isaac
Alignment Tool, within BaseSpace (Illumina). Somatic single nucleotide (SNV) and inser-
tion/deletion (InDel) variant calling analysis was performed using the Tumour-Normal
Application v1.0, based on Strelka, within BaseSpace. Calls were annotated using
VariantStudio v2 (Illumina), a software using variant effect predictor (VEP) v2.8, COSMIC
v77 and 1000 Genomes (v3). In a second approach, data were analyzed using QIAGEN’s
Ingenuity Variant Analysis software (QIAGEN Redwood City).
For copy-number and zygosity detection and analyses, Log2R values were generated
from paired and unpaired tumor and germline data and these, together with B-allele fre-
quency (BAF) outputs, were analyzed and events flagged and visualized using Nexus
Discovery Edition 7.5 (BioDiscovery, Inc., El Segundo, CA).
Translocation events were investigated using BreakDancer (v1.4.5). Analysis was limited
to a set of cancer-specific genes, as previously defined (Huret et al. 2013).
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Presence of HPV was determined by alignment of tumor sample reads using bwa (Li and
Durbin 2009). HPV was confirmed and the HPV-35 subtype further classified by HPVDetector
(Chandrani et al. 2015).
In Silico Whole-Exome Analysis
To explore whether we would have obtained similar or identical results from WES to those
obtained by WGS, we applied an in silico filter using the Agilent SureSelect exome panel.
SNVs, indels, and CNVs were then analyzed as in the WGS analyses described above and
in the main text.
Interpretation of Pathogenicity and Clinical Impact
All SNVs, indels, CNAs, and copy-neutral regions of homozygosity (cnLOHs) were classified
with respect to their pathogenicity and clinical actionability (Futreal et al. 2004) (see
Supplemental Information), information relating to germline and somatic changes at the re-
spective locus was integrated. Analysis of germline changes was limited to a predefined in
silico targeted panel of genes (Supplemental Table S3).
Specifically for defects in the DDR pathway, only inferred homozygous mutations were
classified as clinically actionable. Allelic imbalance was not clinically actionable. For cases
with hypermutated genotype (Cases 5 and 7) only clearly actionable mutations were includ-
ed. A number of different sources, including COSMIC Cancer Genes Census (v77), “My
Cancer Genome” (https://www.mycancergenome.org), and ClinicalTrials.gov (http://
clinicaltrials.gov) were used to determine whether genetic alterations were clinically rele-
vant. Using this information, mutations were classified as tier 1, tier 2, or tier 3 (Li et al.
2017). Tier 1 variants were defined by strong prognostic or diagnostic relevance and/or clin-
ically actionability based on the availability of either an FDA/EMA approved therapy or ac-
cess to clinical trials relevant to the indication. Tier 2 variants were defined as those that
might contribute to confirming the pathological diagnosis or have established biological rel-
evance and/or those for which a clinical trial or approved therapy in a different tumor type
was available. Tier 3 variants are those of unknown significance.
All variants showing annotations of potential clinical significance (tier 1 and 2 variants;
see Table 2) were inspected manually using the integrative genomics viewer (IGV)
(Robinson et al. 2011).
All results were fed back to clinicians in an integrated molecular and histopathological
report overseen by the Genomics Tumour Board consisting of clinicians, senior clinical sci-
entists, bioinformaticians, and histopathologists (Wagle et al. 2012; Dienstmann et al. 2014).
ADDITIONAL INFORMATION
Data Deposition and Access
The tier 1 and tier 2 variants identified in this study have been submitted to ClinVar (https://
www.ncbi.nlm.nih.gov/clinvar/) and can be found under accession numbers SCV000493830
PTEN Chr 10:85557432–105804295 CN Loss; SCV000493831 BRCA2 Chr 13:32178877–
33860144 CN Loss (Homozygous); and SCV000493829 TP53 Chr 17:7573975
NM_000546.5: c1044_1051 delGGAACTCA.
Ethics Statement
Written informed consent was obtained in line with the Declaration of Helsinki and local re-
search ethics committees following the procedures outlined by theOxford Radcliffe Biobank
(South Central-Berkshire B Research Ethics Committee [REC no: 14/SC/1165]).
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